Grufity logo
Grufity logo
RAIN

RAIN - Rain Therapeutics Inc. Stock Price, Fair Value and News

$2.22-0.07 (-3.06%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

RAIN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RAIN Price Action

Last 7 days

5.0%

Last 30 days

32.2%

Last 90 days

-35.0%

RAIN RSI Chart

RAIN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RAIN Valuation

Market Cap

82.6M

Price/Earnings (Trailing)

-1.14

EV/EBITDA

-0.6

Price/Free Cashflow

-1.26

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

RAIN Fundamentals

RAIN Earnings

RAIN Profitability

Free Cashflow Yield

-79.64%

RAIN Investor Care

About Rain Therapeutics Inc.

RAIN
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.
 CEO
 WEBSITErainoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES63

Rain Therapeutics Inc. Frequently Asked Questions

RAIN is the stock ticker symbol of Rain Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Rain Therapeutics Inc. is 82.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.